AU Patent

AU2021201953A1 — Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (HAO1) By Double-Stranded RNA

Assigned to Dicerna Pharmaceuticals Inc · Expires 2021-04-29 · 5y expired

What this patent protects

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HA01) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HA01) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

Patent Metadata

Patent number
AU2021201953A1
Jurisdiction
AU
Classification
—
Expires
2021-04-29
Drug substance claim
No
Drug product claim
No
Assignee
Dicerna Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.